Denver, CO – June 2, 2008 – Results from an analysis assessing the differences in health benefits costs (HBCs) and lost time among employees suffering from multiple sclerosis (MS) being treated with ...
Avonex (interferon beta-1a) may not be safe to use while pregnant or breastfeeding. Certain factors may determine whether you should use the drug during this time. »Learn more about Avonex, including ...
Biogen Idec and Elan’s multiple sclerosis drug Tysabri may have killed patients because of an adverse interaction with the Biogen multiple sclerosis drug Avonex, according to an investors from Ireland ...
AVONEX PEN (interferon beta-1a) 30mcg/0.5mL solution for injection by Biogen Idec Biogen Idec has received approval from the FDA for Avonex Pen (30mcg/0.5mL solution for injection) for patients ...
Avonex (interferon beta-1a) has potential interactions with other medications. For example, Avonex can interact with certain antiretroviral drugs and monoclonal antibodies. Avonex is used in adults to ...
AVONEX PEN (interferon beta-1a) 30mcg/0.5mL solution for injection by Biogen Idec The Avonex Pen (interferon beta-1a 30mcg/0.5mL solution for injection), the first IM autoinjector for chronic use in ...
However, Half of Surveyed Neurologists Do Not Expect to Change Their Prescribing Habits of Copaxone or IFN-beta Therapies by 2012, According to a New Report from Decision Resources WALTHAM, Mass., ...
CAMBRIDGE, Mass.-(BUSINESS WIRE) - Data from an observational phase IV study of 499 patients entitled The Swiss MS Skin Project show that multiple sclerosis (MS) patients taking AVONEX (interferon ...
The late Lawrence Jacobs, MD, a UB professor of neurology, was determined to improve the lives of his patients. His resolve led to groundbreaking research on multiple sclerosis (MS)—most notably the ...
Patients taking the multiple sclerosis (MS) drug Avonex (search) should be watched for possible liver problems, says the drug’s maker. Rare cases of severe liver injury, including cases of liver ...
Ireland’s Elan Corporation received a boost on both ides of the Atlantic on news that its withdrawn multiple sclerosis drug, Tysabri (natalizumab), boosts the efficacy of partner Biogen Idec’s MS ...
BOSTON (MarketWatch) -- Biogen Idec Inc. reported Wednesday its first-quarter profit jumped 23%, thanks to double-digit sales growth for its Avonex and Rituxan drugs. The Cambridge, Mass., biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results